News

The Pharma Proteomics Project, commissioned by a biopharmaceutical consortium, represents a major step forward in ‘proteomics’ and will further enhance the UK Biobank database and research resource.

200,000 participant exomes now accessible for researchers to advance human genetics

UK Biobank has now made available to researchers, a greater wealth of data from newly released linked electronic patient records to enable greater understanding of COVID-19.

UK Biobank, a long-term study of health data from 500,000 UK volunteers, announces today that it is developing its own cloud-based Data Analysis Platform in order to enable its extensive medical data to be accessed more readily by a broader range of researchers around the world.

Data provided by GP practices will be linked to records of existing Biobank participants to aid researchers and scientists in their understanding of COVID-19.

Thousands of UK Biobank participants are being asked to take part in a major government study to measure the extent of coronavirus infection in different regions across the UK.

Crucial new data on the health of 500,000 UK Biobank participants are being made available to scientists tackling the COVID-19 emergency.

A Shrewsbury resident became the 30,000th volunteer at the Stockport assessment centre, which supports the work of two other scanning centres.

Collaboration between UK Biobank, Regeneron and GSK delivers significant new data and genetic insights.

A £200 million investment from government, industry and charity cements UK Biobank’s reputation as a world-leading health resource to tackle the widest range of common and chronic diseases – including dementia, mental illness, cancer and heart disease.